about
Rheumatoid arthritis in Latin America: the importance of an early diagnosisProper management of rheumatoid arthritis in Latin America. What the guidelines say?Is ultrasound a better target than clinical disease activity scores in rheumatoid arthritis with fibromyalgia? A case-control study.The paradox of high availability and low recognition of soluble HLA-G by LILRB1 receptor in rheumatoid arthritis patients.Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases treated with anti-tumor necrosis factor agents.Long-term outcomes of treat-to-target strategy in established rheumatoid arthritis: a daily practice prospective cohort study.Evaluation of polymorphic variants in apoptotic genes and their role in susceptibility and clinical progression to systemic lupus erythematosus.Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians: Differences Across Countries in the METEOR Database.[Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides].Erratum to: Proper management of rheumatoid arthritis in Latin America. What the guidelines say?Association of the HLA-G 14-bp insertion/deletion polymorphism with juvenile idiopathic arthritis and rheumatoid arthritis.Neuromuscular fatigue is weakly associated with perception of fatigue and function in patients with rheumatoid arthritis.Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL.Assessment of nailfold capillaroscopy in systemic sclerosis by different optical magnification methods.Latent tuberculosis infection in patients with rheumatic diseasesCachexia in patients with rheumatoid arthritis: a cohort studyVaccination for patients with rheumatoid arthritis: a pressing need
P50
Q26799803-2310E90B-2799-4225-8C32-86D13C3E2919Q26801231-4788C476-E0C4-467E-98A9-DF34E9B74063Q35147579-FE85BF12-B044-49AE-9F23-1A3AA600676CQ35325312-719CB46F-4C8A-4A91-9C1E-A14679FC9656Q38739251-95EA0099-DB9A-41C1-AD3B-9631DDA8802BQ38907907-770D3CDC-3AC0-40CF-B10A-55C33767B7ACQ39137962-61C205CE-78CD-459E-A98E-E96B995455CEQ40510582-9D8766ED-034F-43E8-82C4-D83BBBA9236AQ41176187-7B76BD8D-7644-4400-8B04-5C2F11463373Q43087163-AC2E4241-1D69-421D-922B-4D790360FF42Q44838586-611C501D-144B-45A3-B16B-CFAD046317B3Q47357520-C2AA1624-DC42-418D-AA5F-8F0DE16C4807Q51036235-FE94C8CA-3778-43A7-ACE3-4F58016B1AD3Q53132181-80A27F4D-64ED-4692-8411-D1845E07D00CQ91638996-FF1BF2A7-B1A9-4816-911F-BAEEC2772B5CQ95649482-B4B1920D-3058-4EF1-A605-48C9F5BF9AF8Q95815119-B1131092-1AF6-4F34-94B3-F0558C4FF3C0
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Claiton Viegas Brenol
@ast
Claiton Viegas Brenol
@en
Claiton Viegas Brenol
@es
Claiton Viegas Brenol
@nl
type
label
Claiton Viegas Brenol
@ast
Claiton Viegas Brenol
@en
Claiton Viegas Brenol
@es
Claiton Viegas Brenol
@nl
prefLabel
Claiton Viegas Brenol
@ast
Claiton Viegas Brenol
@en
Claiton Viegas Brenol
@es
Claiton Viegas Brenol
@nl
P106
P1153
22949929400
P31
P496
0000-0003-0229-7912